PPROM at 29 Weeks with Previous LSCS — Management

Management Algorithm (Creasy & Resnik's Maternal-Fetal Medicine)

Step 1 — Confirm Diagnosis

• Fluid passing per cervical os on speculum examination
• Positive nitrazine/ferning test
• Cervicovaginal biochemical marker testing (IGFBP-1, PAMG-1)
• Avoid digital vaginal examination

Step 2 — Initial Assessment

Step 3 — Expectant/Conservative Management (if no immediate delivery indication)

A. Corticosteroids (most important intervention)

• Betamethasone 12 mg IM × 2 doses, 24 hours apart (or Dexamethasone 6 mg IM × 4 doses, 12 hours apart)
• Reduces RDS, IVH, NEC, and neonatal mortality
• Indicated for all preterm PROM <34 weeks

B. Antibiotics for Latency (NICHD Protocol — standard of care)

• IV Ampicillin 2 g every 6 hours + IV Erythromycin 250 mg every 6 hours × 48 hours
• Followed by oral Amoxicillin 250 mg every 8 hours + oral Erythromycin 333 mg every 8 hours × 5 days
• Avoid Amoxicillin-Clavulanate (co-amoxiclav) — associated with increased risk of neonatal necrotizing enterocolitis
• Alternatives if shortages: oral ampicillin, azithromycin, clarithromycin
• Prolongs pregnancy, reduces chorioamnionitis, reduces neonatal infectious morbidity
• Reduces frequencies of neonatal sepsis, IVH, RDS at <32 weeks' gestation

C. Magnesium Sulfate for Neuroprotection

• Indicated for PPROM before 32 weeks
• MgSO₄ 6 g IV bolus → 2 g/hour infusion × 12 hours (NICHD-MFMU protocol)
• Reduces cerebral palsy (4.2% vs 7.3%; P = .004), IVH, PVL, and developmental delay
• Administer even if delivery is not immediately planned

D. Tocolysis

• Not routinely recommended for prolonging latency in PPROM
• May be considered short-term (48 hours only) to facilitate steroid administration or maternal transfer before 34 weeks, in the absence of infection or abruption
• No prophylactic tocolysis before contractions; therapeutic tocolysis after contractions has no proven benefit
• Extra caution in previous LSCS: uterine scar makes aggressive tocolysis riskier

E. DVT Prophylaxis

• Bed rest increases DVT risk
• Leg exercises, compression stockings, sequential compression devices
• Weigh subcutaneous heparin against bleeding/anaesthesia risks

Step 4 — Fetal Surveillance During Conservative Management

• CTG at least daily (fetal heart rate abnormalities from cord compression occur in 32–76%)
• Biophysical profile (BPP) if NST equivocal — note: BPP may be confounded by oligohydramnios
• Serial USS for fetal growth, AFV, and lower uterine segment thickness

Step 5 — Timing of Delivery

• Planned delivery at 34–37 weeks if conservatively managed and stable
• Immediate delivery at any gestation for: chorioamnionitis, abruption, non-reassuring fetal testing, advanced labor
• In stable patients, plan to deliver by 34 weeks

Key Additional Considerations — Previous LSCS

1. Mode of Delivery

• Previous LSCS is not a contraindication to vaginal delivery in PPROM, but must be individualized
• At 29 weeks, the fetal size is small — vaginal birth after caesarean (VBAC) may be considered
• However, cervical ripening with prostaglandins (misoprostol, PGE₂) is CONTRAINDICATED in a scarred uterus due to high risk of uterine rupture
• If induction is needed, oxytocin is used cautiously with continuous CTG monitoring
• If labour fails to progress or there are signs of scar dehiscence → emergency LSCS

2. Uterine Rupture Risk

• Prior LSCS scars carry ~0.5–0.9% uterine rupture risk in labour (higher with prior classical/inverted-T incisions)
• Classical caesarean scar (vertical uterine incision): much higher rupture risk — elective repeat LSCS strongly preferred regardless of PPROM
• Continuous intrapartum CTG is mandatory — variable/late decelerations, sudden fetal bradycardia, loss of uterine contraction pattern, maternal haemorrhage = warning signs
• Lower threshold for proceeding to repeat LSCS if labour does not progress well

3. Placenta Praevia / Morbid Placentation

• In previous LSCS, rule out placenta praevia/accreta/increta/percreta by USS — these mandate delivery by LSCS
• If placenta praevia confirmed → elective repeat LSCS, not expectant vaginal management

4. Intrapartum GBS Prophylaxis

• Regardless of prior antibiotic therapy, intrapartum GBS prophylaxis is required if:
  • GBS carrier known
  • Carrier status unknown and delivering preterm

5. NICU Availability

• Conservative management must occur in a centre with Level III NICU and capacity for emergency LSCS
• If not available, arrange in-utero transfer

Summary Framework

• Creasy & Resnik's Maternal-Fetal Medicine: Principles and Practice, Chapter 39 — Management of Premature Rupture of the Membranes
• ACOG Practice Bulletin on Prelabor Rupture of Membranes